Malaria
LONDON — The chief executive of the world’s second biggest pharmaceutical company will announce Jan. 20 that he is putting into the public domain thousands of potential drugs that might cure malaria, The Guardian reported.
Andrew Witty, CEO of Glaxo-SmithKline, will say in a major speech that multinational drug companies have to balance social responsibility alongside the need to make profits for their shareholders. There is, he will say, an “imperative to earn the trust of society, not just by meeting expectations but by exceeding them.”
GSK will publish details of 13,500 chemical compounds from its own library that have potential to act against the parasite that causes malaria in sub-Saharan Africa, killing at least 1 million children every year.
It took a team of five investigators a year to screen the 2 million compounds in GSK’s library — its entire collection of potential drugs and possibly the biggest such library in the world.
The move was given a cautious welcome by charities such as Médecins Sans Frontières (aka Doctors Without Borders), although Oxfam questioned whether other big drug companies would want to develop treatments from GSK patents.
Witty, though, said he thinks scientists would and should seize the opportunity.
Speaking to The Guardian in advance of the announcement in New York, he said: “To my knowledge nobody’s ever put confirmed-hit structures into the public domain. Universities have done stuff like this but on a much smaller scale.
“I think it’s a significant contribution to give scientists around the world 13,500 new opportunities to start research.”
Witty will also announce an $8 million fund to pay for scientists to explore these chemicals or others in an “open lab” within its research center at Tres Cantos, Spain, which is dedicated to work on malaria and other diseases of the developing world.
“It’s trying to create a permissiveness around scientific research in an area where we know the marketplace isn’t going to stimulate massive research,” he said.
“Given that there is only a handful of big companies who focus on malaria, this is a chance to get thousands of researchers involved — just like software companies encourage thousands of people to contribute their new ideas for software — and we’ll see what comes of it.”
While it was pleased at GSK’s new initiatives and praised the leadership the company had shown, Oxfam in effect accused Witty of naivety in thinking that other drug giants would come on board.
“Last year he announced some new, interesting ideas. But they stayed for a whole year as ideas. GSK should know how the industry works. As long as this is run by one company, others are not going to join in,” said Dr. Mohga Kamal-Yanni, the charity’s senior health adviser. “I’m glad they realize now they need to do more than just put ideas on the table.
“It is quite exciting what they have decided to do, but we have to watch whether it becomes something interesting at the end of the day.”
Tido von Schoen-Angerer, director of Doctors Without Borders’ campaign for essential medicines, said: “The fact that they are opening up their compounds for malaria is a good step. It is something like we have been calling for for some years. It would be good if other companies would do the same thing, and for other diseases.”
